Pharmaceutical giant Bayer has announced plans to buy 100 percent of Germany-based private pharmaceutical conglomerate Steigerwalk Arzneimittelwerk. Financial details of the deal were not released in a press release; the parties expect to close the deal by July 2013, though it remains subject to approval by antitrust regulators. According to Bayer, the move is part of a larger agenda to promote “organic growth” and expand its product offering for consumers. According to a press release, the move will also expand business for Bayer throughout Germany and east-central Europe.
Featured News
Court Allows Class Action Against Meta Over Facebook Data Breach
Apr 14, 2026 by
CPI
California Lawmakers Clash Over Controversial Antitrust Expansion Bill
Apr 14, 2026 by
CPI
SEC Issues Statement Allowing DeFi Interfaces to Skip Registering as Broker-Dealers
Apr 14, 2026 by
CPI
FTC Set to Enforce Sweeping COPPA Updates Expanding Compliance Burdens
Apr 14, 2026 by
CPI
European Commission Clears Telecom Deals in Italy and Spain
Apr 14, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers